- Home
- GLPG vs VITL Comparison
GLPG vs VITL Comparison
Compare GLPG & VITL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- VITL
- Stock Information
- Founded
- GLPG 1999
- VITL 2007
- Country
- GLPG Belgium
- VITL United States
- Employees
- GLPG N/A
- VITL N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- VITL Packaged Foods
- Sector
- GLPG Health Care
- VITL Consumer Staples
- Exchange
- GLPG Nasdaq
- VITL Nasdaq
- Market Cap
- GLPG 2.0B
- VITL 1.6B
- IPO Year
- GLPG 2005
- VITL 2020
- Fundamental
- Price
- GLPG $32.98
- VITL $36.91
- Analyst Decision
- GLPG Sell
- VITL Strong Buy
- Analyst Count
- GLPG 4
- VITL 9
- Target Price
- GLPG $25.33
- VITL $44.00
- AVG Volume (30 Days)
- GLPG 372.1K
- VITL 703.8K
- Earning Date
- GLPG 07-23-2025
- VITL 08-07-2025
- Dividend Yield
- GLPG N/A
- VITL N/A
- EPS Growth
- GLPG N/A
- VITL 30.46
- EPS
- GLPG N/A
- VITL 1.13
- Revenue
- GLPG $323,674,692.00
- VITL $620,567,000.00
- Revenue This Year
- GLPG $0.78
- VITL $25.33
- Revenue Next Year
- GLPG N/A
- VITL $19.59
- P/E Ratio
- GLPG N/A
- VITL $33.17
- Revenue Growth
- GLPG 5.43
- VITL 23.96
- 52 Week Low
- GLPG $22.36
- VITL $27.91
- 52 Week High
- GLPG $33.86
- VITL $45.72
- Technical
- Relative Strength Index (RSI)
- GLPG 64.82
- VITL 53.02
- Support Level
- GLPG $31.98
- VITL $35.59
- Resistance Level
- GLPG $33.51
- VITL $41.42
- Average True Range (ATR)
- GLPG 0.84
- VITL 1.55
- MACD
- GLPG 0.13
- VITL -0.26
- Stochastic Oscillator
- GLPG 82.68
- VITL 36.51
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About VITL Vital Farms Inc.
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).